Introduction Rybrevant is the brand name of amivantamab-vmjw, an anticancer biologic used in selected patients with non-small cell lung cancer, commonly abbreviated as NSCLC. Pharmacologically, Rybrevant is a bispecific antibody directed against two important receptor targets: epidermal growth factor receptor, or EGFR, and MET receptor. NSCLC is a major type of lung cancer. In some … Read more
Introduction Sotorasib is an oral targeted anticancer drug marketed under the brand name Lumakras. Pharmacologically, sotorasib is a KRAS G12C inhibitor and belongs to the class of RAS GTPase inhibitors. KRAS is an important intracellular signaling protein involved in cell growth, proliferation, differentiation, survival, and apoptosis regulation. Normally, KRAS works like a molecular switch. It … Read more
Introduction Amivantamab is a targeted anticancer monoclonal antibody used in selected patients with non-small cell lung cancer, commonly abbreviated as NSCLC. It is marketed under the brand name Rybrevant as intravenous amivantamab-vmjw. A subcutaneous formulation, Rybrevant Faspro, contains amivantamab with hyaluronidase-lpuj, but the key anticancer antibody component is amivantamab. Pharmacologically, amivantamab is a bispecific antibody … Read more
Introduction Trametinib is an oral targeted anticancer drug marketed under the brand name Mekinist. Pharmacologically, trametinib belongs to the mitogen-activated extracellular signal-regulated kinase inhibitor class, commonly called MEK inhibitors. MEK1 and MEK2 are important kinases in the RAS-RAF-MEK-ERK signaling pathway. This pathway regulates cell growth, proliferation, survival, differentiation, and migration. In several cancers, mutations in … Read more
